Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 22153890

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2012 Jan
First author
Gianni L

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2012 Jan;13(1):2-3. doi: 10.1016/S1470-2045(11)70388-6.
    note
    Source null
    related pmid
    22225715
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2012 Jan 10;9(2):67. doi: 10.1038/nrclinonc.2011.205.
    note
    Source null
    related pmid
    22231751
    relationship
    Comment in

Authors and identifiers

  1. name
    Gianni L
    type
    Author
  2. name
    Pienkowski T
    type
    Author
  3. name
    Im YH
    type
    Author
  4. name
    Roman L
    type
    Author
  5. name
    Tseng LM
    type
    Author
  6. name
    Liu MC
    type
    Author
  7. name
    Lluch A
    type
    Author
  8. name
    Staroslawska E
    type
    Author
  9. name
    de la Haba-Rodriguez J
    type
    Author
  10. name
    Im SA
    type
    Author
  11. name
    Pedrini JL
    type
    Author
  12. name
    Poirier B
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gianni L
    type
    Author
  2. name
    Pienkowski T
    type
    Author
  3. name
    Im YH
    type
    Author
  4. name
    Roman L
    type
    Author
  5. name
    Tseng LM
    type
    Author
  6. name
    Liu MC
    type
    Author
  7. name
    Lluch A
    type
    Author
  8. name
    Staroslawska E
    type
    Author
  9. name
    de la Haba-Rodriguez J
    type
    Author
  10. name
    Im SA
    type
    Author
  11. name
    Pedrini JL
    type
    Author
  12. name
    Poirier B
    type
    Author
bibliography ids
  1. nci-bib-ec3f1c5592d22e0a657532ff
book metadata
content sha256
09218fb516c8845bd671725367f97f0b7c06dd8c6b4cca29ca98ea86a8686b45
document type
citation
dois
  1. 10.1016/S1470-2045(11)70336-9
electronic publication date
display
2011 Dec 6
precision
day
year
2011
evidence scope
bibliographic_metadata_only
id
pubmed:22153890
immutable id
pubmed:22153890@09218fb516c8845bd671725367f97f0b7c06dd8c6b4cca29ca98ea86a8686b45
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
25-32
volume
13
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2012 Jan;13(1):2-3. doi: 10.1016/S1470-2045(11)70388-6.
    note
    Source null
    related pmid
    22225715
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2012 Jan 10;9(2):67. doi: 10.1038/nrclinonc.2011.205.
    note
    Source null
    related pmid
    22231751
    relationship
    Comment in
outcomes validated
false
pmid
22153890
provenance
batch id
b6284687e167e7da9556
provider
NCBI PubMed ESummary
record sha256
c8a87f2cb3c6c40d46fc4da18e5889ec0ff4e99bbdbbb5e7a0e31c2c9246a82a
response sha256
64d5b7bb63f574c559af2523b779a262267cbc8e8cd02a5b47f4193cc95cabd3
retrieved at
2026-09-09T23:46:45.216259+00:00
publication date
display
2012 Jan
precision
month
year
2012
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/22153890/
title
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Preserved source evidence · Not medical advice